StocksFin Logo
Zealand Pharma A/S country of incorporation
|
|
Dr. Emmanuel Dulac Ph.D., PharmD, MBA
|
237 employees
NASDAQ | Healthcare | Biotechnology
Silence Therapeutics plc country of incorporation
|
|
Mr. Mark Andrew Rothera
|
105 employees
NASDAQ | Healthcare | Biotechnology
Q122 reported Mar 31, 2022 Reporting Period
$15.08M -68.5% vs. Q121 Revenues Q122
80.69% 60.2% vs. Q121 Gross Profit Margin
-1000% ! -97.4% vs. Q121 Net Profit Margin
-320.75M ! 12.9% vs. Q121 Free Cash Flow Q122
$-5.16 ! 10.7% vs. Q121 EPS Q122
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q122
Q322
Q322 reported Sep 30, 2022 Reporting Period
$3.37M 6.8% vs. Q321 Revenues Q322
28.98% -17.1% vs. Q321 Gross Profit Margin
-210.71% ! 33% vs. Q321 Net Profit Margin
-9.45M ! -91.8% vs. Q321 Free Cash Flow Q322
$-0.22 ! 35.1% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q122
Q322
Loading...
Loading...
Ratios
As of
Mar 31, 2022
Sep 30, 2022
Quick Ratio
3.68
3.98
Current Ratio
4.79
4.37
Cash Ratio
3.4
3.47
Price to Book
6.04
7.06
Price to Sales
100
71.52
Price to Earnings
-4.81
-8.49